Lancet Regional Health-Europe最新文献

{"title":"E-cigarettes: public health saviour or Trojan Horse?","authors":"The Lancet Regional Health – Europe","doi":"10.1016/j.lanepe.2024.100997","DOIUrl":"https://doi.org/10.1016/j.lanepe.2024.100997","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666776224001649/pdfft?md5=d5542829d22d0c8df35c523ac7be9157&pid=1-s2.0-S2666776224001649-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141483427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The potential of climatic suitability indicator for Leishmania transmission modelling in Europe: insights and suggested directions","authors":"Shlomit Paz","doi":"10.1016/j.lanepe.2024.100995","DOIUrl":"https://doi.org/10.1016/j.lanepe.2024.100995","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666776224001625/pdfft?md5=9fea248a47e3f108e4bc1f81a488300c&pid=1-s2.0-S2666776224001625-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141479736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Political economy dichotomy in primary health care: bridging the gap between reality and necessity","authors":"Dheepa Rajan , Melitta Jakab , Gerard Schmets , Natasha Azzopardi-Muscat , Juliane Winkelmann , David Peiris , Erica Di Ruggiero , Tracey Naledi , Adelson Guaraci Jantsch , Thiago Trindade , Nyawira Gitahi , Suszy Lessof , Faraz Khalid , Suraya Dalil , Josep Figueras","doi":"10.1016/j.lanepe.2024.100945","DOIUrl":"10.1016/j.lanepe.2024.100945","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666776224001121/pdfft?md5=770ce947374100d8430f571c9f461d33&pid=1-s2.0-S2666776224001121-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141136431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research on novel E-cigarette products","authors":"Thomas A. Wills","doi":"10.1016/j.lanepe.2024.100959","DOIUrl":"10.1016/j.lanepe.2024.100959","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666776224001261/pdfft?md5=777815a3621c41b8a886affb04861ddd&pid=1-s2.0-S2666776224001261-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141415631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in incidence of pneumothorax in England before, during and after the COVID-19 pandemic (2017–2023): a population-based observational study","authors":"Xiaomin Zhong ,&nbsp;Raph Goldacre ,&nbsp;Eva J.A. Morris ,&nbsp;Rob J. Hallifax","doi":"10.1016/j.lanepe.2024.100994","DOIUrl":"https://doi.org/10.1016/j.lanepe.2024.100994","url":null,"abstract":"<div><h3>Background</h3><p>COVID-19 is a risk factor for pneumothorax. The pandemic may have influenced healthcare-seeking behaviour for pneumothorax. This study aimed to investigate recent trends in the incidence of pneumothorax in England.</p></div><div><h3>Methods</h3><p>A population-based epidemiological study was conducted using an English national dataset of hospital admissions (Hospital Episode Statistics) from 2017 to 2023. Record-linkage was used to identify multiple admissions per person and co-morbidity. Pneumothoraces co-occurring with COVID-19 were identified by concurrent COVID-19 diagnostic coding. The pre-pandemic (January 2017–February 2020), pandemic (March-2020–February-2021) and post-pandemic periods (March 2021–March 2023) were compared.</p></div><div><h3>Findings</h3><p>From 2017 to 2023, there were 72,275 hospital admissions for spontaneous pneumothorax among 59,130 patients. Admissions showed marked variability, peaking in January 2021 when the rate of admissions was about two-thirds higher than that of the pre-pandemic level (Incidence rate ratio [IRR] 1.65, 95% CI: 1.48–1.84). However, when excluding patients with a concurrent COVID-19 diagnosis, the overall trend shifted to a reduction during the pandemic period. Post-pandemic rates were not significantly different from pre-pandemic levels (IRR = 0.96, 95% CI: 0.89–1.04). The incidence of spontaneous pneumothorax was significantly higher in males (rate ratio compared to females: 2.29, 95% CI: 2.19–2.39). However, the trends were consistent in both males and females.</p></div><div><h3>Interpretation</h3><p>This study highlights a significant peak in COVID-19 related cases but a corresponding trough in non-COVID-related cases (end 2020, early 2021). Despite a previous report of increasing incidence of (non-COVID-related) hospitalised spontaneous pneumothorax over the long-term between 1968 and 2016, we did not observe any continued increase throughout this study period, prompting further investigation into the impact of recent guidelines.</p></div><div><h3>Funding</h3><p>Authors are supported by the <span>NIHR</span> Oxford BRC, Li Ka Shing and <span>Robertson Foundations</span>, <span>MRC</span>, and HDR UK.</p></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666776224001613/pdfft?md5=13c6d368047ca1cb95eedc21361339c8&pid=1-s2.0-S2666776224001613-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141486242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maternal, prenatal and postnatal risk factors for early child physical abuse: a French nationwide cohort study","authors":"Flora Blangis ,&nbsp;Jérôme Drouin ,&nbsp;Elise Launay ,&nbsp;Sara Miranda ,&nbsp;Mahmoud Zureik ,&nbsp;Jérémie F. Cohen ,&nbsp;Alain Weill ,&nbsp;Rosemary Dray-Spira ,&nbsp;Martin Chalumeau","doi":"10.1016/j.lanepe.2024.100921","DOIUrl":"10.1016/j.lanepe.2024.100921","url":null,"abstract":"<div><h3>Background</h3><p>Identifying risk factors for early child physical abuse (CPA) is crucial for understanding its mechanisms and defining effective preventive interventions. We aimed to identify maternal, prenatal and postnatal factors associated with early CPA.</p></div><div><h3>Methods</h3><p>This cohort study was based on comprehensive data from the Mother-Child EPI-MERES nationwide register and included all infants born alive in France between 2010 and 2019. Factors associated with early CPA (before age 1) were identified with a multilevel Cox regression model with random intercepts at the regional level.</p></div><div><h3>Findings</h3><p>Among the 6,897,384 included infants, 2994 (40/100,000) had a diagnosis of early CPA, at a median age of 4 months. Independent factors most strongly associated with early CPA were maternal low financial resources (adjusted hazard ratio [aHR] 1.91; 95% confidence interval [95% CI] 1.67–2.18), maternal age &lt;20 years versus 35–40 years (aHR 7.06; 95% CI 6.00–8.31), maternal alcohol use disorder (aHR 1.85; 95% CI 1.48–2.31), opioid use disorder (aHR 1.90; 95% CI 1.41–2.56), intimate partner violence (aHR 3.33; 95% CI 2.76–4.01), diagnosis of a chronic mental disorder (aHR 1.50; 95% CI 1.14–1.97) or somatic disorder (aHR 1.55; 95% CI 1.32–1.83), hospitalisation for a mental disorder (aHR 1.88; 95% CI 1.49–2.36), very preterm birth (aHR 2.15; 95% CI 1.68–2.75), and diagnosis of a chronic severe neurocognitive disorder in the infant (aHR 14.37; 95% CI 11.85–17.44).</p></div><div><h3>Interpretation</h3><p>Independent risk factors of early CPA identified at the national level in France may help in understanding CPA mechanisms and developing effective prevention programs including risk-stratification tools to optimise the allocation of parenting interventions to parents who could most benefit from them.</p></div><div><h3>Funding</h3><p><span>Ile-de-France regional council</span>, L'Oréal-UNESCO For Women In Science France Young Talent Award, French <span>National Observatory for Child Protection [ONPE]</span>, <span>French Association of Ambulatory Paediatrics [AFPA]</span>, <span>HUGO university hospitals network</span>, <span>Mustela Foundation and Sauver la Vie prizes</span>.</p></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666776224000887/pdfft?md5=0fc16a50d88810254e3abee40dc460c8&pid=1-s2.0-S2666776224000887-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141029133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The dark side of light: light at night may raise the risk of type 2 diabetes","authors":"Pei Xue,&nbsp;Diana A. Nôga,&nbsp;Christian Benedict","doi":"10.1016/j.lanepe.2024.100955","DOIUrl":"10.1016/j.lanepe.2024.100955","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666776224001224/pdfft?md5=968f310afa213d27677c0745913902f5&pid=1-s2.0-S2666776224001224-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141397704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smartphone application versus written material for smoking reduction and cessation in individuals undergoing low-dose computed tomography (LDCT) screening for lung cancer: a phase II open-label randomised controlled trial","authors":"Sanna Iivanainen ,&nbsp;Antti Kurtti ,&nbsp;Viktor Wichmann ,&nbsp;Heidi Andersen ,&nbsp;Antti Jekunen ,&nbsp;Riitta Kaarteenaho ,&nbsp;Tuula Vasankari ,&nbsp;Jussi P. Koivunen","doi":"10.1016/j.lanepe.2024.100946","DOIUrl":"https://doi.org/10.1016/j.lanepe.2024.100946","url":null,"abstract":"<div><h3>Background</h3><p>Counseling, nicotine replacement, and other cessation medications have been proven effective in smoking cessation. The wide-scale adoption of smartphones and other mobile devices has opened new possibilities for scalable and personalized smoking cessation approaches. The study investigated whether a smartphone application would be more effective than written material for smoking cessation and reduction in smoking in individuals undergoing low-dose computed tomography (LDCT) screening for lung cancer (NCT05630950).</p></div><div><h3>Methods</h3><p>This randomized controlled trial enrolled 201 current smokers with marked smoking history (smoked ≥15 cigarettes/day for ≥25 years or smoked ≥10 cigarettes/day for ≥30 years). Participants were stratified by age and pack-years and randomized in 1:1 fashion to the developed smartphone application (experimental arm) or written material (standard of care). All the subjects underwent LDCT screening. Self-reported smoking cessation at three and six months were the primary endpoints of the study. The smoking-related secondary endpoints of the study were the percentage of individuals who had reduced the number of smoked cigarettes/d from the baseline.</p></div><div><h3>Findings</h3><p>Between Nov 18, 2022, and Apr 14, 2023, 201 patients were screened at Oulu University Hospital, Finland, of whom all were randomly assigned to smartphone application (n = 101) or written cessation material (n = 100); 200 were included in the full analysis set. Study arms were well-balanced for all the studied demographic factors. Subjects randomized to the smartphone application arm had significantly higher rates for self-reported smoking cessation at three (19.8 versus 7.1%; OR 3.175 CI 95% 1.276–7.899) and six months (18.8 versus 7.1%; OR 2.847 CI 95% 1.137–7.128). In the experimental arm, individuals with a frequent use of the application had a higher chance for smoking cessation at three (p &lt; 0.001) and six months (p = 0.003).</p></div><div><h3>Interpretation</h3><p>The study showed that the developed smartphone application increases the likelihood for smoking cessation in individuals undergoing lung cancer LDCT screening.</p></div><div><h3>Funding</h3><p><span>AstraZeneca</span>, <span>Roche</span>, and <span>Cancer Foundation Finland</span>.</p></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666776224001133/pdfft?md5=4c08a2b3c146fe6349f5f49e2ecbbafd&pid=1-s2.0-S2666776224001133-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141482016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reaching the ideal cardiovascular health: is this the key to preventing multiple long-term conditions?","authors":"Yogini V. Chudasama,&nbsp;Kamlesh Khunti","doi":"10.1016/j.lanepe.2024.100968","DOIUrl":"https://doi.org/10.1016/j.lanepe.2024.100968","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666776224001352/pdfft?md5=e8598bbbd6439367816b317750c57a2d&pid=1-s2.0-S2666776224001352-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141482036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study","authors":"Adrien Rousseau ,&nbsp;Stefan Michiels ,&nbsp;Noémie Simon-Tillaux ,&nbsp;Alexandre Lolivier ,&nbsp;Julia Bonastre ,&nbsp;David Planchard ,&nbsp;Fabrice Barlesi ,&nbsp;Jordi Remon ,&nbsp;Pernelle Lavaud ,&nbsp;Mihaela Aldea ,&nbsp;Maxime Frelaut ,&nbsp;Cecile Le Pechoux ,&nbsp;Angela Botticella ,&nbsp;Antonin Levy ,&nbsp;Anas Gazzah ,&nbsp;Stephanie Foulon ,&nbsp;Benjamin Besse","doi":"10.1016/j.lanepe.2024.100970","DOIUrl":"https://doi.org/10.1016/j.lanepe.2024.100970","url":null,"abstract":"<div><h3>Background</h3><p>The efficacy of front-line pembrolizumab has been established in studies that limit treatment duration to 2 years, but decision to stop pembrolizumab after 2 years is often at physician's discretion. ATHENA is a retrospective cohort study using a comprehensive administrative database aimed firstly at exploring the optimal duration of pembrolizumab and secondly real-life prognosis factors in patients with advanced non-small cell lung cancer (NSCLC).</p></div><div><h3>Methods</h3><p>Using the French National Health Insurance database (SNDS), we identified patients with incident lung cancer in France from 2015 to 2022. Treatments and patients' characteristics were extracted or inferred from hospital, outpatient care, pharmacy delivery reports. The duration's hazard ratio (HR) was estimated with Cox model weighted by inverse of propensity score to account for confounding. Prognostics factors in first line population were identified with Cox model selected by a LASSO procedure.</p></div><div><h3>Findings</h3><p>391,106 patients with lung cancer were identified, of whom 43,359 received up-front pembrolizumab for an advanced disease. There were 67% (29,040/43,359) of male and the median age at diagnosis was 65 years old. After a median follow-up time of 25.9 months (min–max, [0–97.6]), the median overall survival (OS) after pembrolizumab initiation in first line was 15.7 [CI 95, 15.3–16.0] months. In multivariable analysis, several covariables were independently associated with worse OS, including male sex with chemo-immunotherapy, age, hospital category, high deprivation index, inpatient hospitalization for first pembrolizumab, and history of diabetes, diuretic, beta blocker, painkiller prescription. At landmark time of 29 months after pembrolizumab initiation, continuation beyond 2 years was not associated with better OS than a fixed 2-year treatment, HR = 0.97 [0.75–1.26] p = 0.95.</p></div><div><h3>Interpretation</h3><p>This study supports the notion that stopping pembrolizumab after 2 years could be safe for patients with advanced NSCLC. However, because observational studies are prone to confounding and selection bias, causality cannot be affirmed.</p></div><div><h3>Funding</h3><p>This study did not receive any specific grant.</p></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666776224001376/pdfft?md5=bb7ff8a52b9907f556544bb4758cd466&pid=1-s2.0-S2666776224001376-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141479716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}